thrombocytopenia with TPO or other TPORA ineffective
Conditions
Interventions
Sponsors
The Forth Affiliated Hospital Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, male or female; 2. ECOG PS score of physical condition: 0-2 points; 3. Platelet count = 3 months; 6. Those who have not participated in clinical trials of other drugs within 4 weeks before enrollment; 7. Subjects fully understand and voluntarily participate in this study and sign informed consent; 8. Those who are expected to have good compliance can follow up the efficacy and adverse reactions according to the program requirements.
Exclusion criteria
Exclusion criteria: 1. Any history of arterial or venous thrombosis within 6 months before screening; 2. Severe cardiovascular disease (such as NYHA cardiac function score III-IV) within 6 months before screening, arrhythmias known to increase the risk of thromboembolism such as atrial fibrillationatrial fluttercoronary stenting, angioplasty patients after coronary artery bypass grafting and coronary artery bypass grafting;; 3. Patients with known or expected hypersensitivity or intolerance to the active ingredients or excipients of avatrombopag; 4. Women in pregnancy, preparation for pregnancy or breast feeding period; 5. Serious neurological or psychiatric history; 6. Unsuitable subjects for this study determined by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Effective time;Cumulative number of days of platelet response;Safety; | — |
Countries
China
Contacts
Public ContactHuang Jian
The Forth Affiliated Hospital Zhejiang University School of Medicine
Outcome results
None listed